Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 11/26 02:06:21 am
84.55 EUR   +0.39%
11/25How will Canada's COVID-19 vaccine program work?
RE
11/25SANOFI : EC approves new meningitis vaccine
AQ
11/25EXPLAINER : When and how will COVID-19 vaccines become available?
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
85.64(c) 85.85(c) 84.09(c) 84.21(c) 84.22(c) Last
2 231 095 2 882 348 1 796 901 2 422 873 2 515 815 Volume
-0.52% +0.25% -2.05% +0.14% +0.01% Change
More quotes
Financials
Sales 2020 36 357 M 43 398 M 43 398 M
Net income 2020 11 732 M 14 004 M 14 004 M
Net Debt 2020 7 972 M 9 516 M 9 516 M
P/E ratio 2020 9,04x
Yield 2020 3,79%
Sales 2021 37 829 M 45 155 M 45 155 M
Net income 2021 5 851 M 6 984 M 6 984 M
Net Debt 2021 5 763 M 6 879 M 6 879 M
P/E ratio 2021 17,7x
Yield 2021 3,98%
Capitalization 106 B 126 B 126 B
EV / Sales 2020 3,13x
EV / Sales 2021 2,95x
Nbr of Employees 100 409
Free-Float 89,0%
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (84.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs; - human vaccines (15.9%): pediatric vaccines,... 
Sector
Pharmaceuticals
Calendar
02/05Earnings Release
More about the company
Notations Surperformance© of Sanofi
Trading Rating : Investor Rating :
More Ratings
All news about SANOFI
11/25How will Canada's COVID-19 vaccine program work?
RE
11/25SANOFI : EC approves new meningitis vaccine
AQ
11/25EXPLAINER : When and how will COVID-19 vaccines become available?
RE
11/24SANOFI : - European Commission approves MenQuadfi, the latest innovation in meni..
AQ
11/24EU secures 160 million doses of Moderna's COVID-19 vaccine
RE
11/23SANOFI : Disclosure of trading in own shares
AQ
11/23SANOFI : Disclosure of trading in own shares
GL
11/23SANOFI : European Commission approves MenQuadfi®, the latest innovation in menin..
PU
11/23SANOFI : European Commission approves MenQuadfi®, the latest innovation in menin..
AQ
11/23SANOFI : European Commission approves MenQuadfi®, the latest innovation in menin..
GL
11/23SANOFI : European Commission approves MenQuadfi®, the latest innovation in menin..
AQ
11/19SANOFI : - Rilzabrutinib granted FDA Fast Track Designation for treatment of imm..
AQ
11/19SANOFI : - European Commission approves Supemtek for the prevention of influenza..
AQ
11/19SANOFI : - FDA grants priority review for avalglucosidase alfa, a potential new ..
AQ
11/19ROCHE : Actemra helps the sickest COVID-19 patients, study shows
RE
More news
News in other languages on SANOFI
11/25La rémunération des dirigeants du CAC 40 en baisse de 10% en 2019 (rapport)
11/24Coronavirus-Macron ne veut pas de vaccination obligatoire
11/24EU schließt Impfstoff-Vertrag mit Moderna ab
11/24CORONAVIRUS : l'UE annonce un contrat de vaccins avec Moderna
11/24Europäer bekommen auch aussichtsreichen Moderna-Impfstoff
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 11/19
A trend reversal can be anticipated
BUY
More Stock Trading Analysis
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 103,49 €
Last Close Price 84,22 €
Spread / Highest target 40,1%
Spread / Average Target 22,9%
Spread / Lowest Target 0,93%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-6.03%126 012
JOHNSON & JOHNSON-1.50%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-1.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273